ABT Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
Abbott Laboratories (ABT) has shown strong fundamentals, with a 91% rating from Validea's P/E/Growth Investor model, indicating solid valuation and growth prospects in the Medical Equipment & Supplies industry. The company is expected to report an EPS of $1.07 for the upcoming quarter, reflecting a 9.18% increase from the previous year.
Technical Analysis:
The stock is trading above its 20, 50, 60, and 200-day moving averages, signaling a strong uptrend. The RSI_14 of 39.18 suggests the stock is not overbought, and the MACD is showing early signs of a bullish crossover. Fibonacci levels indicate a pivot point at 130.93, with resistance at 136.53 and support at 125.33.
News Sentiment:
Abbott recently reached its average analyst target price, which may lead to upward revisions. The stock has underperformed the market slightly but is expected to gain momentum ahead of its earnings report.
Price Prediction:
Based on the analysis, the stock is expected to rise to $136.53 next week, encountering resistance at this level.
Recommendation:
Buy Abbott Laboratories (ABT) as the technical setup and strong fundamentals support further upside, despite potential volatility around earnings.
ABT Similar Chart Price Prediction
The price of ABT is predicted to go up -4.55%, based on the high correlation periods with CIX. The similarity of these two price pattern on the periods is 96.77%.
ABT
CIX
Down: -4.55%Similarity: 96.77%
ABT Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
ABT Price Forecast($)
Potential Return(%)
2025
113.930
0.090
2026
150.000
8.690
2027
175.000
26.800
2028
175.000
26.800
2029
180.000
30.430
2030
200.000
44.920
What is ABT stock price prediction 2025 ?
What is ABT stock price prediction 2026 ?
What is ABT stock price prediction 2027 ?
What is ABT stock price prediction 2028 ?
What is ABT stock price prediction 2029 ?
What is ABT stock price prediction 2030 ?
ABT Revenue Forecast
ABT EPS Forecast
ABT FAQs
What is ABT revenue forecast for next quarter？
What is ABT eps forecast for next quarter？
ABT VS S&P500
Abbott has been investing in structural heart products and recently entered the left atrial appendage closure market.
Early results from an investigational clinical trial on the Tendyne transcatheter mitral valve were favorable. If the pivotal trial results are favorable, this could give a boost to Abbott's structural heart unit.
Abbott's sale of its established pharma business in developed markets to Mylan and its acquisition of CFR and Veropharm have put the branded generics business in a strong position to benefit from growing demand in emerging markets.
ABT Analyst's Forecast
Joanne Wuensch
Citigroup
Strong Buy
2025-03-04
Price Target
$135 → $160
Upside
+14.89%
Citi raised the firm's price target on Abbott to $160 from $135 and keeps a Buy rating on the shares. The analyst also added a "90-day negative catalyst watch" on the shares. The stock "will need to test the litigation waters before further ascent," the analyst tells investors in a research note. Citi, however, raised estimates for Abbott to reflect the company's Q4 strength and momentum.
Rick Wise
Stifel
Strong Buy
2025-01-23
Price Target
$130 → $135
Upside
+10.54%
Danielle Antalffy
UBS
Strong Buy
2025-01-23
Price Target
$146 → $148
Upside
+21.18%
